VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis

Cellular Immunology

Volumn 267, Issue 2, 2011, Pages 124-132

  Yadav, Mahesh ^a   Huang, Mei Chuan ^a   Goetzl, Edward J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Colitis; DSS; VIP; VIP receptors; VPAC1; VPAC2

Indexed keywords

CHEMOKINE RECEPTOR CCR6; DEXTRAN SULFATE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MYELOPEROXIDASE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; BODY WEIGHT; COLITIS; COLON; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PEROXIDASE; PROTEIN KINASE INHIBITORS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; VASOACTIVE INTESTINAL PEPTIDE;

MURINAE; MUS;

EID: 79751526267     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.01.001     Document Type: Article

References (46)

1. Dorsam G., Voice J., Kong Y., Goetzl E.J. Vasoactive intestinal peptide mediation of development and functions of T lymphocytes. Ann. NY Acad. Sci. 2000, 921:79-91.
2. Goetzl E.J., Adelman D.C., Sreedharan S.P. Neuroimmunology. Adv. Immunol. 1990, 48:161-190.
3. Sami V.M., Said I. Vasointestinal peptide and related peptides. Ann. NY Acad. Sci. 1988, 527:1-691.
4. Bellinger D.L., Lorton D., Brouxhon S., Felten S., Felten D.L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmunol. 1996, 6:5-27.
5. Martinez C., Delgado M., Abad C., Gomariz R.P., Ganea D., Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 1999, 93:126-138.
6. Voice J.K., Dorsam G., Chan R.C., Grinninger C., Kong Y., Goetzl E.J. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul. Pept. 2002, 109:199-208.
7. Delgado M., Martinez C., Johnson M.C., Gomariz R.P., Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 1996, 68:27-38.
8. Langer I., Robberecht P. Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors. Biochem. Soc. Trans. 2007, 35:724-728.
9. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D., Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leukoc. Biol. 1998, 63:591-601.
10. Qian B.F., Hammarstrom M.L., Danielsson A. Differential expression of vasoactive intestinal polypeptide receptor 1 and 2 mRNA in murine intestinal T lymphocyte subtypes. J. Neuroendocrinol. 2001, 13:818-825.
11. Johnston J.A., Taub D.D., Lloyd A.R., Conlon K., Oppenheim J.J., Kevlin D.J. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. J. Immunol. 1994, 153:1762-1768.
12. Voice J.K., Dorsam G., Lee H., Kong Y., Goetzl E.J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 2001, 15:2489-2496.
13. Xia M., Gaufo G.O., Wang Q., Sreedharan S.P., Goetzl E.J. Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors. J. Immunol. 1996, 157:1132-1138.
14. Yadav M., Goetzl E.J. Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity. Ann. NY Acad. Sci. 2008, 1144:83-89.
15. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 1999, 162:1707-1716.
16. Goetzl E.J., Voice J.K., Shen S., Dorsam G., Kong Y., West K.M., Morrison C.F., Harmar A.J. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. USA 2001, 98:13854-13859.
17. Odum L., Petersen L.J., Skov P.S., Ebskov L.B. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm. Res. 1998, 47:488-492.
18. + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009, 326:986-991.
19. Sun W., Hong J., Zang Y.C., Liu X., Zhang J.Z. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int. Immunol. 2006, 18:1691-1700.
20. Voice J.K., Grinninger C., Kong Y., Bangale Y., Paul S., Goetzl E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol. 2003, 170:308-314.
21. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 1982, 78:206-209.
22. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 2008, 8:337-348.
23. Abad C., Martinez C., Juarranz M.G., Arranz A., Leceta J., Delgado M., Gomariz R.P. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003, 124:961-971.
24. Dewit D., Gourlet P., Amraoui Z., Vertongen P., Willems F., Robberecht P., Goldman M. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol. Lett. 1998, 60:57-60.
25. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 1996, 6:61-74.
26. Yadav M., Rosenbaum J., Goetzl E.J. Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J. Immunol. 2008, 180:2772-2776.
27. Ottaway C.A. In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells. J. Exp. Med. 1984, 160:1054-1069.
28. Yukawa T., Oshitani N., Yamagami H., Watanabe K., Higuchi K., Arakawa T. Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease. Int. J. Mol. Med. 2007, 20:161-167.
29. Arai Y., Takanashi H., Kitagawa H., Okayasu I. Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. Cytokine 1998, 10:890-896.
30. Dieleman L.A., Palmen M.J., Akol H., Bloemena E., Pena A.S., Meuwissen S.G., Van Rees E.P. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 1998, 114:385-391.
31. Fielding C.A., McLoughlin R.M., McLeod L., Colmont C.S., Najdovska M., Grail D., Ernst M., Jones S.A., Topley N., Jenkins B.J. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 2008, 181:2189-2195.
32. Kahler C.M., Pischel A., Kaufmann G., Wiedermann C.J. Influence of neuropeptides on neutrophil adhesion and transmigration through a lung fibroblast barrier in vitro. Exp. Lung Res. 2001, 27:25-46.
33. Gross K.J., Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm. Bowel Dis. 2007, 13:918-932.
34. Smalley S.G., Barrow P.A., Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin. Exp. Immunol. 2009, 157:225-234.
35. Gomariz R.P., Martinez C., Abad C., Leceta J., Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des. 2001, 7:89-111.
36. Bienenstock J., Tomioka M., Matsuda H., Stead R.H., Quinonez G., Simon G.T., Coughlin M.D., Denburg J.A. The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions. Int. Arch. Allergy Immunol. 1987, 82:238-243.
37. Surrenti C., Renzi D., Garcea M.R., Surrenti E., Salvadori G. Colonic vasoactive intestinal polypeptide in ulcerative colitis. J. Physiol. Paris 1993, 87:307-311.
38. Hokari R., Lee H., Crawley S.C., Yang S.C., Gum J.R., Miura S., Kim Y.S. Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G949-G959.
39. Laburthe M., Augeron C., Rouyer-Fessard C., Roumagnac I., Maoret J.J., Grasset E., Laboisse C. Functional VIP receptors in the human mucus-secreting colonic epithelial cell line CL.16E. Am. J. Physiol. 1989, 256:G443-G450.
40. O'Connor W., Kamanaka M., Booth C.J., Town T., Nakae S., Iwakura Y., Kolls J.K., Flavell R.A. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 2009, 10:603-609.
41. Ogawa A., Andoh A., Araki Y., Bamba T., Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 2004, 110:55-62.
42. Baugh M.D., Perry M.J., Hollander A.P., Davies D.R., Cross S.S., Lobo A.J., Taylor C.J., Evans G.S. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999, 117:814-822.
43. Santana A., Medina C., Paz-Cabrera M.C., Diaz-Gonzalez F., Farre E., Salas A., Radomski M.W., Quintero E. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J. Gastroenterol. 2006, 12:6464-6472.
44. Alex P., Zachos N.C., Nguyen T., Gonzales L., Chen T.E., Conklin L.S., Centola M., Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. D 2009, 15:341-352.
45. Stead R.H. Innervation of mucosal immune cells in the gastrointestinal tract. Reg. Immunol. 1992, 4:91-99.
46. Margolis K.G., Gershon M.D. Neuropeptides and inflammatory bowel disease. Curr. Opin. Gastroenterol. 2009, 25:503-511.